{"id":90320,"date":"2026-06-23T07:30:48","date_gmt":"2026-06-23T07:30:48","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/90320\/"},"modified":"2026-06-23T07:30:48","modified_gmt":"2026-06-23T07:30:48","slug":"roche-to-pay-nurix-up-to-2-3-billion-for-experimental-cancer-drug-rights","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/90320\/","title":{"rendered":"Roche to Pay Nurix Up to $2.3 Billion for Experimental Cancer Drug Rights"},"content":{"rendered":"<p class=\"ArticleBodyText_articleBodyContent__17wqE typography_articleBody___5jDr\" data-component=\"paragraph\"><a href=\"https:\/\/www.bloomberg.com\/quote\/ROP:SW\" target=\"_blank\" rel=\"noopener nofollow\" class=\"media-ui-Link_link-tVkXhPLPofs-\" data-component=\"link\">Roche Holding AG<\/a> agreed to pay <a href=\"https:\/\/www.bloomberg.com\/quote\/NRIX:US\" target=\"_blank\" rel=\"noopener nofollow\" class=\"media-ui-Link_link-tVkXhPLPofs-\" data-component=\"link\">Nurix Therapeutics Inc.<\/a> as much as $2.3 billion for rights to an experimental blood-cancer drug, betting it can help patients whose disease stops responding to existing treatments.<\/p>\n<p class=\"ArticleBodyText_articleBodyContent__17wqE typography_articleBody___5jDr\" data-component=\"paragraph\">Nurix will receive $700 million upfront for bexobrutideg, a pill being developed for certain blood cancers and potentially other immune-system and neurological diseases, Roche <a href=\"https:\/\/www.bloomberg.com\/news\/terminal\/TGAR80TVI5MU\" class=\"media-ui-Link_link-tVkXhPLPofs- whitespace-normal\" target=\"_blank\" rel=\"noopener nofollow\" data-component=\"link\">saidBloomberg Terminal<\/a> Monday. The firms will share development costs and split US profits equally, and Roche will commercialize the therapy outside the US.<\/p>\n","protected":false},"excerpt":{"rendered":"Roche Holding AG agreed to pay Nurix Therapeutics Inc. as much as $2.3 billion for rights to an&hellip;\n","protected":false},"author":2,"featured_media":90321,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[22207,2112,197,70,4128,23121,10622,2521,41514,304,134,473],"class_list":["post-90320","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-americas","tag-cancer","tag-europe","tag-government","tag-healthcare","tag-industrials","tag-industries","tag-new-york","tag-nurix-therapeutics-inc","tag-pharmaceutical","tag-roche","tag-roche-holding-ag"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116798258028148302","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/90320","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=90320"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/90320\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/90321"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=90320"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=90320"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=90320"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}